Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Menarini Asia-Pacific's Glen Godresse on reshaping biopharma commercialisation across Asia

17 August 2026 · By · Wire by Fusion42

Published

17 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Asia-Pacific

◆ Source

Read at biospectrumasia.com →

◆ Verified

Fusion42 · 17 August 2026 · Fusion42 review

Menarini Asia-Pacific is shifting biopharma commercialisation strategies by prioritising early regional market entry and partnering to leverage combined regional and local expertise, exemplified by its partnership with Pharmacosmos to commercialise Cosela in multiple Asia-Pacific markets starting in 2028.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must rethink your market entry to combine regional scale with local agility or risk slow expansion. Menarini’s approach means you can leverage regional lessons while tailoring to diverse Asia-Pacific markets for faster patient access.

◆ Coverage

1 source · 17 Aug 2026

◆ Related on Wire

◆ Topics

Biotechasia-pacificbiopharmacommercialisationregional-partnershipsmarket-entry